Internal medicine

Immunotherapy

Cancer

Oncology

Lung cancer

Nivolumab

Ipilimumab

Medicine

New England Journal of Medicine

In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC.

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer